Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News

Pledge the Gift of Life

Each year, the lives of thousands of people across the country are saved because someone made the choice to become an organ donor. In April, Allegheny Health Network is honored to celebrate National Donate Life Month and pay tribute to all of those who have bestowed the precious gift of life to another through organ donation. Visit AHNdonate.org to learn more and register to be an organ donor.



Format: 04/18/2014
Format: 04/18/2014


CNBC-TV: Failed Avastin early-stage cancer study detailed

Tuesday, June 2nd, 2009

A study of blockbuster drug Avastin in colon cancer patients who have undergone surgery showed that the drug's effectiveness wore off after patients stopped taking it, researchers said on Saturday.

As previously disclosed by the drug's maker, Roche Holding AG's Genentech unit, the 2,710-patient trial did not meet its main goal of showing an extension in disease-free survival. Newly released details show that 77.4 percent of patients in the Avastin group were alive and free of disease after a median follow-up of three years, compared with 75.5 percent of patients in the control group, a difference that was not statistically significant.

But at the one-year mark, Avastin was shown to reduce the risk of cancer recurrence or death by about 40 percent. This result proves that the drug is active in early-stage cancer, said Phillippe Bishop, head of clinical development for Avastin at Genentech. The trial was designed to show whether use of Avastin plus chemotherapy for six months, followed by six months of Avastin alone, results in more patients being cancer free after three years compared with just treating them with chemotherapy.

"As patients come off treatment, the events come back," Bishop said. "The one-year duration of treatment was insufficient to derive clinical benefit."

This was the first trial which sought to show Avastin's ability to prevent cancer recurrence by wiping out microscopic cancer cells that may remain in the body after tumors have been removed by surgery, known as use in the "adjuvant" setting. But several similar trials are under way, including a second in early-stage colon cancer patients for which results are expected next year.

Since all of the current adjuvant trials of Avastin also have treatment durations of one year, there is little expectation that results will be encouraging. Bishop said the latest findings, presented here at a meeting of the American Society of Clinical Oncology, are influencing Roche/Genentech's ongoing clinical trial program for Avastin.

The drug, known chemically as bevacizumab, is an antibody designed to fight cancer by interfering with the blood supply to tumors. A month of Avastin treatment costs about $4,400. The drug, which has annual sales of about $4.4 billion, is currently approved for treating metastatic colorectal, breast, lung and later-stage brain cancers. Use in earlier-stage cancer patients would drive even more sales.

"There was a transient benefit in disease-free survival during the one year that bevacizumab was given," said Dr Norman Wolmark, chairman of the Department of Human Oncology at Allegheny General Hospital and the study's lead author.

To read more, visit CNBC-TV's web site.

West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 3 + 3 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.